Use of discard pleural fluid in molecular research

Grannis, Frederic W.

doi:10.1038/nrclinonc.2011.114-c1

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have demonstrated the capacity of similar integrated pipelines to verify numerous candidates from proteome or transcriptome data sets. , In this study, we applied our pipeline to a unique proximal fluid, exudative PE, that is mainly caused by infectious diseases or malignancy. Exudative PE was used as a research material because (i) it can be collected with minimal additional risk and fewer ethical concerns for patients as part of a clinically indicated thoracentesis, , (ii) exudative PEs caused by various diseases are highly heterogeneous, (iii) candidates can be generated directly from serous fluid at proximal cancer sites with less of a dilution factor and less interference from other organs, and (iv) the current diagnostic method for MPE lacks sufficient sensitivity. MPE is also advantageous for the discovery of novel cancer biomarkers because proteins that are elevated in response to common inflammation can be excluded using two infectious diseases (PN and TB) as controls.…”

Section: Discussionmentioning

confidence: 99%

Targeted Proteomics Pipeline Reveals Potential Biomarkers for the Diagnosis of Metastatic Lung Cancer in Pleural Effusion

Chen¹,

Wang

Yu³

et al. 2014

J. Proteome Res.

View full text Add to dashboard Cite

The ability to discriminate lung cancer malignant pleural effusion (LC-MPE) from benign pleural effusion has profound implications for the therapy and prognosis of lung cancer. Here, we established a pipeline to verify potential biomarkers for this purpose. In the discovery phase, label-free quantification was performed for the proteome profiling of exudative pleural effusion in order to select 34 candidate biomarkers with significantly elevated levels in LC-MPE. In the verification phase, signature peptides for 34 candidates were first confirmed by accurate inclusion mass screening (AIMS). To quantify the candidates in PEs, multiple reaction monitoring mass spectrometry (MRM-MS) with stable isotope-labeled standards (SIS) peptides was performed for the 34 candidate biomarkers using the QconCAT approach for the generation of the SIS peptides. The results of the MRM assay were used to prioritize candidates based on their discriminatory power in 82 exudative PE samples. The five potential biomarkers (ALCAM, CDH1, MUC1, SPINT1, and THBS4; AUC > 0.7) and one three-marker panel (SPINT1/SVEP1/THBS4; AUC = 0.95) were able to effectively differentiate LC-MPE from benign PE. Collectively, these results demonstrate that our pipeline is a feasible platform for verifying potential biomarkers for human diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeted Proteomics Pipeline Reveals Potential Biomarkers for the Diagnosis of Metastatic Lung Cancer in Pleural Effusion

Chen¹,

Wang

Yu³

et al. 2014

J. Proteome Res.

View full text Add to dashboard Cite

show abstract

“…We categorize each biofluid with regard to fluid volume (mL), cellularity (cells/mL), fluid viscosity, and associated diseases. For some of these biofluids, researchers can gain access to remnant samples after all diagnostic tests are performed with expedited IRB review, which can speed investigation into simple approaches to prepare and analyze these diagnostically important fluids beyond blood 18 .…”

Section: Background and Applications Of Biofluidsmentioning

confidence: 99%

Microfluidic sample preparation for diagnostic cytopathology

2013

View full text Add to dashboard Cite

The cellular components of body fluids are routinely analyzed to identify disease and treatment approaches. While significant focus has been placed on developing cell analysis technologies, tools to automate the preparation of cellular specimens have been more limited, especially for body fluids beyond blood. Preparation steps include separating, concentrating, and exposing cells to reagents. Sample preparation continues to be routinely performed off-chip by technicians, preventing cell-based point-of-care diagnostics, increasing the cost of tests, and reducing the consistency of the final analysis following multiple manually-performed steps. Here, we review the assortment of biofluids for which suspended cells are analyzed, along with their characteristics and diagnostic value. We present an overview of the conventional sample preparation processes for cytological diagnosis. We finally discuss the challenges and opportunities in developing microfluidic devices for the purpose of automating or miniaturizing these processes, with particular emphases on preparing large or small volume samples, working with samples of high cellularity, automating multi-step processes, and obtaining high purity subpopulations of cells. We hope to convey the importance of and help identify new research directions addressing the vast biological and clinical applications in preparing and analyzing the array of available biological fluids. Successfully addressing the challenges described in this review can lead to inexpensive systems to improve diagnostic accuracy while simultaneously reducing overall systemic healthcare costs.

show abstract